Literature DB >> 25365432

Prenatal care, pregnancy outcomes, and postpartum birth control plans among pregnant women with opiate addictions.

Anna Beth Parlier1, Blake Fagan1, Melinda Ramage1, Shelley Galvin1.   

Abstract

OBJECTIVES: To describe how effectively we provided adequate prenatal care and postpartum contraception to prevent repeat, unintended pregnancies to women using opiates or medication maintenance therapy (MMT) during pregnancy.
METHODS: We conducted a retrospective chart review of 94 women using opiates or MMT during 96 pregnancies while receiving prenatal care in the regional high-risk maternity care clinic between July 2010 and June 2012. We examined prenatal care usage, birth outcomes, and postpartum contraception using χ(2), Kruskal-Wallis, and binary logistic regression modeling.
RESULTS: Patients were predominately white (93.6%), multiparous (75.5%), and in their 20s; 71 (74%) used MMT and 25 (26%) used prescribed or illicit opiates. Fewer than half (44% [46.2%]) received any documented prenatal counseling about postpartum contraception. Sixteen (17%) babies were premature. Sixty-four (66.7%) infants were diagnosed as having neonatal abstinence syndrome (NAS). Only 42 (43.8%) women attended their postpartum visits. Overall, 60 (62.5%) women received postpartum contraception. The only significant predictors of postpartum contraception use were preterm birth and postpartum appointment attendance.
CONCLUSIONS: Alternative strategies for providing postpartum care should be explored because women using opiates or MMT during pregnancy are significantly more likely to use postpartum contraception if they attend their postpartum appointments.

Entities:  

Mesh:

Year:  2014        PMID: 25365432     DOI: 10.14423/SMJ.0000000000000189

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

1.  Postpartum contraceptive use and interpregnancy interval among women with opioid use disorder.

Authors:  Elizabeth E Krans; Joo Yeon Kim; Alton Everette James; David K Kelley; Marian Jarlenski
Journal:  Drug Alcohol Depend       Date:  2018-02-14       Impact factor: 4.492

2.  The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts.

Authors:  Milton Kotelchuck; Erika R Cheng; Candice Belanoff; Howard J Cabral; Hermik Babakhanlou-Chase; Taletha M Derrington; Hafsatou Diop; Stephen R Evans; Judith Bernstein
Journal:  Matern Child Health J       Date:  2017-04

3.  The impact of Medicaid expansion on postpartum health care utilization among pregnant women with opioid use disorder.

Authors:  Briana P Patton; Elizabeth E Krans; Joo Yeon Kim; Marian Jarlenski
Journal:  Subst Abus       Date:  2019-03-25       Impact factor: 3.716

4.  Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation.

Authors:  Uma M Reddy; Jonathan M Davis; Zhaoxia Ren; Michael F Greene
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.623

5.  Air Pollution and Preterm Birth in the U.S. State of Georgia (2002-2006): Associations with Concentrations of 11 Ambient Air Pollutants Estimated by Combining Community Multiscale Air Quality Model (CMAQ) Simulations with Stationary Monitor Measurements.

Authors:  Hua Hao; Howard H Chang; Heather A Holmes; James A Mulholland; Mitch Klein; Lyndsey A Darrow; Matthew J Strickland
Journal:  Environ Health Perspect       Date:  2015-10-20       Impact factor: 9.031

6.  Postpartum Visit Attendance Increases the Use of Modern Contraceptives.

Authors:  Saba W Masho; Susan Cha; RaShel Charles; Elizabeth McGee; Nicole Karjane; Linda Hines; Susan G Kornstein
Journal:  J Pregnancy       Date:  2016-12-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.